Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 149

1.

Protective immunity in recurrent Staphylococcus aureus infection reflects localized immune signatures and macrophage-conferred memory.

Chan LC, Rossetti M, Miller LS, Filler SG, Johnson CW, Lee HK, Wang H, Gjertson D, Fowler VG Jr, Reed EF, Yeaman MR; MRSA Systems Immunobiology Group.

Proc Natl Acad Sci U S A. 2018 Oct 8. pii: 201808353. doi: 10.1073/pnas.1808353115. [Epub ahead of print]

PMID:
30297395
2.

Methodologies for in vitro and in vivo evaluation of efficacy of antifungal and antibiofilm agents and surface coatings against fungal biofilms.

Van Dijck P, Sjollema J, Cammue BP, Lagrou K, Berman J, d'Enfert C, Andes DR, Arendrup MC, Brakhage AA, Calderone R, Cantón E, Coenye T, Cos P, Cowen LE, Edgerton M, Espinel-Ingroff A, Filler SG, Ghannoum M, Gow NAR, Haas H, Jabra-Rizk MA, Johnson EM, Lockhart SR, Lopez-Ribot JL, Maertens J, Munro CA, Nett JE, Nobile CJ, Pfaller MA, Ramage G, Sanglard D, Sanguinetti M, Spriet I, Verweij PE, Warris A, Wauters J, Yeaman MR, Zaat SAJ, Thevissen K.

Microb Cell. 2018 Jun 14;5(7):300-326. doi: 10.15698/mic2018.07.638. Review.

3.

Human Anti-Als3p Antibodies Are Surrogate Markers of NDV-3A Vaccine Efficacy Against Recurrent Vulvovaginal Candidiasis.

Uppuluri P, Singh S, Alqarihi A, Schmidt CS, Hennessey JP Jr, Yeaman MR, Filler SG, Edwards JE, Ibrahim AS.

Front Immunol. 2018 Jun 15;9:1349. doi: 10.3389/fimmu.2018.01349. eCollection 2018.

4.

Role of Purine Biosynthesis in Persistent Methicillin-Resistant Staphylococcus aureus Infection.

Li L, Abdelhady W, Donegan NP, Seidl K, Cheung A, Zhou YF, Yeaman MR, Bayer AS, Xiong YQ.

J Infect Dis. 2018 Sep 22;218(9):1367-1377. doi: 10.1093/infdis/jiy340.

PMID:
29868791
5.

Regulated Cell Death as a Therapeutic Target for Novel Antifungal Peptides and Biologics.

Yeaman MR, Büttner S, Thevissen K.

Oxid Med Cell Longev. 2018 Apr 26;2018:5473817. doi: 10.1155/2018/5473817. eCollection 2018. Review.

6.

The Hyr1 protein from the fungus Candida albicans is a cross kingdom immunotherapeutic target for Acinetobacter bacterial infection.

Uppuluri P, Lin L, Alqarihi A, Luo G, Youssef EG, Alkhazraji S, Yount NY, Ibrahim BA, Bolaris MA, Edwards JE Jr, Swidergall M, Filler SG, Yeaman MR, Ibrahim AS.

PLoS Pathog. 2018 May 10;14(5):e1007056. doi: 10.1371/journal.ppat.1007056. eCollection 2018 May.

7.

A Fungal Immunotherapeutic Vaccine (NDV-3A) for Treatment of Recurrent Vulvovaginal Candidiasis-A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial.

Edwards JE Jr, Schwartz MM, Schmidt CS, Sobel JD, Nyirjesy P, Schodel F, Marchus E, Lizakowski M, DeMontigny EA, Hoeg J, Holmberg T, Cooke MT, Hoover K, Edwards L, Jacobs M, Sussman S, Augenbraun M, Drusano M, Yeaman MR, Ibrahim AS, Filler SG, Hennessey JP Jr.

Clin Infect Dis. 2018 Jun 1;66(12):1928-1936. doi: 10.1093/cid/ciy185.

PMID:
29697768
8.

Clonally expanded γδ T cells protect against Staphylococcus aureus skin reinfection.

Dillen CA, Pinsker BL, Marusina AI, Merleev AA, Farber ON, Liu H, Archer NK, Lee DB, Wang Y, Ortines RV, Lee SK, Marchitto MC, Cai SS, Ashbaugh AG, May LS, Holland SM, Freeman AF, Miller LG, Yeaman MR, Simon SI, Milner JD, Maverakis E, Miller LS.

J Clin Invest. 2018 Mar 1;128(3):1026-1042. doi: 10.1172/JCI96481. Epub 2018 Feb 5.

9.

Innovative Approaches to Improve Anti-Infective Vaccine Efficacy.

Yeaman MR, Hennessey JP Jr.

Annu Rev Pharmacol Toxicol. 2017 Jan 6;57:189-222. doi: 10.1146/annurev-pharmtox-010716-104718. Review.

PMID:
28061685
10.

Innate Immune Memory Contributes to Host Defense against Recurrent Skin and Skin Structure Infections Caused by Methicillin-Resistant Staphylococcus aureus.

Chan LC, Chaili S, Filler SG, Miller LS, Solis NV, Wang H, Johnson CW, Lee HK, Diaz LF, Yeaman MR.

Infect Immun. 2017 Jan 26;85(2). pii: e00876-16. doi: 10.1128/IAI.00876-16. Print 2017 Feb.

11.

Restoring immune tolerance in neuromyelitis optica: Part II.

Bar-Or A, Steinman L, Behne JM, Benitez-Ribas D, Chin PS, Clare-Salzler M, Healey D, Kim JI, Kranz DM, Lutterotti A, Martin R, Schippling S, Villoslada P, Wei CH, Weiner HL, Zamvil SS, Smith TJ, Yeaman MR.

Neurol Neuroimmunol Neuroinflamm. 2016 Sep 7;3(5):e277. doi: 10.1212/NXI.0000000000000277. eCollection 2016 Oct. Review.

12.

Restoring immune tolerance in neuromyelitis optica: Part I.

Steinman L, Bar-Or A, Behne JM, Benitez-Ribas D, Chin PS, Clare-Salzler M, Healey D, Kim JI, Kranz DM, Lutterotti A, Martin R, Schippling S, Villoslada P, Wei CH, Weiner HL, Zamvil SS, Yeaman MR, Smith TJ.

Neurol Neuroimmunol Neuroinflamm. 2016 Sep 7;3(5):e276. doi: 10.1212/NXI.0000000000000276. eCollection 2016 Oct. Review.

13.

The Global Regulon sarA Regulates β-Lactam Antibiotic Resistance in Methicillin-Resistant Staphylococcus aureus In Vitro and in Endovascular Infections.

Li L, Cheung A, Bayer AS, Chen L, Abdelhady W, Kreiswirth BN, Yeaman MR, Xiong YQ.

J Infect Dis. 2016 Nov 1;214(9):1421-1429. Epub 2016 Aug 19.

14.

Binding of Daptomycin to Anionic Lipid Vesicles Is Reduced in the Presence of Lysyl-Phosphatidylglycerol.

Khatib TO, Stevenson H, Yeaman MR, Bayer AS, Pokorny A.

Antimicrob Agents Chemother. 2016 Jul 22;60(8):5051-3. doi: 10.1128/AAC.00744-16. Print 2016 Aug.

15.

The GraS Sensor in Staphylococcus aureus Mediates Resistance to Host Defense Peptides Differing in Mechanisms of Action.

Chaili S, Cheung AL, Bayer AS, Xiong YQ, Waring AJ, Memmi G, Donegan N, Yang SJ, Yeaman MR.

Infect Immun. 2015 Nov 23;84(2):459-66. doi: 10.1128/IAI.01030-15. Print 2016 Feb.

16.

Nonredundant Roles of Interleukin-17A (IL-17A) and IL-22 in Murine Host Defense against Cutaneous and Hematogenous Infection Due to Methicillin-Resistant Staphylococcus aureus.

Chan LC, Chaili S, Filler SG, Barr K, Wang H, Kupferwasser D, Edwards JE Jr, Xiong YQ, Ibrahim AS, Miller LS, Schmidt CS, Hennessey JP Jr, Yeaman MR.

Infect Immun. 2015 Nov;83(11):4427-37. doi: 10.1128/IAI.01061-15. Epub 2015 Sep 8.

17.

Update on biomarkers in neuromyelitis optica.

Melamed E, Levy M, Waters PJ, Sato DK, Bennett JL, John GR, Hooper DC, Saiz A, Bar-Or A, Kim HJ, Pandit L, Leite MI, Asgari N, Kissani N, Hintzen R, Marignier R, Jarius S, Marcelletti J, Smith TJ, Yeaman MR, Han MH, Aktas O, Apiwattanakul M, Banwell B, Bichuetti D, Broadley S, Cabre P, Chitnis T, De Seze J, Fujihara K, Greenberg B, Hellwig K, Iorio R, Jarius S, Klawiter E, Kleiter I, Lana-Peixoto M, Nakashima, O'Connor K, Palace J, Paul F, Prayoonwiwat N, Ruprecht K, Stuve O, Tedder T, Tenembaum S, Garrahan JP, Aires B, van Herle K, van Pelt D, Villoslada P, Waubant E, Weinshenker B, Wingerchuk D, Würfel J, Zamvil S.

Neurol Neuroimmunol Neuroinflamm. 2015 Jul 23;2(4):e134. doi: 10.1212/NXI.0000000000000134. eCollection 2015 Aug. Review.

18.

Use of Advanced Magnetic Resonance Imaging Techniques in Neuromyelitis Optica Spectrum Disorder.

Kremer S, Renard F, Achard S, Lana-Peixoto MA, Palace J, Asgari N, Klawiter EC, Tenembaum SN, Banwell B, Greenberg BM, Bennett JL, Levy M, Villoslada P, Saiz A, Fujihara K, Chan KH, Schippling S, Paul F, Kim HJ, de Seze J, Wuerfel JT; Guthy-Jackson Charitable Foundation (GJCF) Neuromyelitis Optica (NMO) International Clinical Consortium and Biorepository, Cabre P, Marignier R, Tedder T, van Pelt D, Broadley S, Chitnis T, Wingerchuk D, Pandit L, Leite MI, Apiwattanakul M, Kleiter I, Prayoonwiwat N, Han M, Hellwig K, van Herle K, John G, Hooper DC, Nakashima I, Sato D, Yeaman MR, Waubant E, Zamvil S, Stüve O, Aktas O, Smith TJ, Jacob A, O'Connor K.

JAMA Neurol. 2015 Jul;72(7):815-22. doi: 10.1001/jamaneurol.2015.0248. Review.

19.

B lymphocytes in neuromyelitis optica.

Bennett JL, O'Connor KC, Bar-Or A, Zamvil SS, Hemmer B, Tedder TF, von Büdingen HC, Stuve O, Yeaman MR, Smith TJ, Stadelmann C.

Neurol Neuroimmunol Neuroinflamm. 2015 May 7;2(3):e104. doi: 10.1212/NXI.0000000000000104. eCollection 2015 Jun. Review.

20.

Challenges and opportunities in designing clinical trials for neuromyelitis optica.

Weinshenker BG, Barron G, Behne JM, Bennett JL, Chin PS, Cree BA, de Seze J, Flor A, Fujihara K, Greenberg B, Higashi S, Holt W, Khan O, Knappertz V, Levy M, Melia AT, Palace J, Smith TJ, Sormani MP, Van Herle K, VanMeter S, Villoslada P, Walton MK, Wasiewski W, Wingerchuk DM, Yeaman MR; Guthy-Jackson Charitable Foundation International Clinical Consortium.

Neurology. 2015 Apr 28;84(17):1805-15. doi: 10.1212/WNL.0000000000001520. Epub 2015 Apr 3. Review.

21.

Early agr activation correlates with vancomycin treatment failure in multi-clonotype MRSA endovascular infections.

Abdelhady W, Chen L, Bayer AS, Seidl K, Yeaman MR, Kreiswirth BN, Xiong YQ.

J Antimicrob Chemother. 2015 May;70(5):1443-52. doi: 10.1093/jac/dku547. Epub 2015 Jan 5.

22.

Mechanisms of NDV-3 vaccine efficacy in MRSA skin versus invasive infection.

Yeaman MR, Filler SG, Chaili S, Barr K, Wang H, Kupferwasser D, Hennessey JP Jr, Fu Y, Schmidt CS, Edwards JE Jr, Xiong YQ, Ibrahim AS.

Proc Natl Acad Sci U S A. 2014 Dec 23;111(51):E5555-63. doi: 10.1073/pnas.1415610111. Epub 2014 Dec 8.

23.

A liaR deletion restores susceptibility to daptomycin and antimicrobial peptides in multidrug-resistant Enterococcus faecalis.

Reyes J, Panesso D, Tran TT, Mishra NN, Cruz MR, Munita JM, Singh KV, Yeaman MR, Murray BE, Shamoo Y, Garsin D, Bayer AS, Arias CA.

J Infect Dis. 2015 Apr 15;211(8):1317-25. doi: 10.1093/infdis/jiu602. Epub 2014 Oct 31.

24.

Applying Convergent Immunity to Innovative Vaccines Targeting Staphylococcus aureus.

Yeaman MR, Filler SG, Schmidt CS, Ibrahim AS, Edwards JE Jr, Hennessey JP Jr.

Front Immunol. 2014 Sep 26;5:463. doi: 10.3389/fimmu.2014.00463. eCollection 2014. Review.

25.

Heterogeneity of mprF sequences in methicillin-resistant Staphylococcus aureus clinical isolates: role in cross-resistance between daptomycin and host defense antimicrobial peptides.

Bayer AS, Mishra NN, Sakoulas G, Nonejuie P, Nast CC, Pogliano J, Chen KT, Ellison SN, Yeaman MR, Yang SJ.

Antimicrob Agents Chemother. 2014 Dec;58(12):7462-7. doi: 10.1128/AAC.03422-14. Epub 2014 Oct 6.

26.

Site-specific mutation of the sensor kinase GraS in Staphylococcus aureus alters the adaptive response to distinct cationic antimicrobial peptides.

Cheung AL, Bayer AS, Yeaman MR, Xiong YQ, Waring AJ, Memmi G, Donegan N, Chaili S, Yang SJ.

Infect Immun. 2014 Dec;82(12):5336-45. doi: 10.1128/IAI.02480-14. Epub 2014 Oct 6.

27.

Phenotypic and genotypic characterization of daptomycin-resistant methicillin-resistant Staphylococcus aureus strains: relative roles of mprF and dlt operons.

Mishra NN, Bayer AS, Weidenmaier C, Grau T, Wanner S, Stefani S, Cafiso V, Bertuccio T, Yeaman MR, Nast CC, Yang SJ.

PLoS One. 2014 Sep 16;9(9):e107426. doi: 10.1371/journal.pone.0107426. eCollection 2014.

28.

Platelets: at the nexus of antimicrobial defence.

Yeaman MR.

Nat Rev Microbiol. 2014 Jun;12(6):426-37. doi: 10.1038/nrmicro3269. Review.

PMID:
24830471
29.

Impact of vancomycin on sarA-mediated biofilm formation: role in persistent endovascular infections due to methicillin-resistant Staphylococcus aureus.

Abdelhady W, Bayer AS, Seidl K, Moormeier DE, Bayles KW, Cheung A, Yeaman MR, Xiong YQ.

J Infect Dis. 2014 Apr 15;209(8):1231-40. doi: 10.1093/infdis/jiu007. Epub 2014 Jan 7.

30.

CotH3 mediates fungal invasion of host cells during mucormycosis.

Gebremariam T, Liu M, Luo G, Bruno V, Phan QT, Waring AJ, Edwards JE Jr, Filler SG, Yeaman MR, Ibrahim AS.

J Clin Invest. 2014 Jan;124(1):237-50. doi: 10.1172/JCI71349. Epub 2013 Dec 20.

31.

Nafcillin enhances innate immune-mediated killing of methicillin-resistant Staphylococcus aureus.

Sakoulas G, Okumura CY, Thienphrapa W, Olson J, Nonejuie P, Dam Q, Dhand A, Pogliano J, Yeaman MR, Hensler ME, Bayer AS, Nizet V.

J Mol Med (Berl). 2014 Feb;92(2):139-49. doi: 10.1007/s00109-013-1100-7. Epub 2013 Dec 3.

32.

NDV-3 protects mice from vulvovaginal candidiasis through T- and B-cell immune response.

Ibrahim AS, Luo G, Gebremariam T, Lee H, Schmidt CS, Hennessey JP Jr, French SW, Yeaman MR, Filler SG, Edwards JE Jr.

Vaccine. 2013 Nov 12;31(47):5549-56. doi: 10.1016/j.vaccine.2013.09.016. Epub 2013 Sep 21.

33.

Emergence of daptomycin resistance in daptomycin-naïve rabbits with methicillin-resistant Staphylococcus aureus prosthetic joint infection is associated with resistance to host defense cationic peptides and mprF polymorphisms.

Mishra NN, Yang SJ, Chen L, Muller C, Saleh-Mghir A, Kuhn S, Peschel A, Yeaman MR, Nast CC, Kreiswirth BN, Crémieux AC, Bayer AS.

PLoS One. 2013 Aug 19;8(8):e71151. doi: 10.1371/journal.pone.0071151. eCollection 2013.

34.

Role of the LytSR two-component regulatory system in adaptation to cationic antimicrobial peptides in Staphylococcus aureus.

Yang SJ, Xiong YQ, Yeaman MR, Bayles KW, Abdelhady W, Bayer AS.

Antimicrob Agents Chemother. 2013 Aug;57(8):3875-82. doi: 10.1128/AAC.00412-13. Epub 2013 Jun 3.

35.

Bcr1 functions downstream of Ssd1 to mediate antimicrobial peptide resistance in Candida albicans.

Jung SI, Finkel JS, Solis NV, Chaili S, Mitchell AP, Yeaman MR, Filler SG.

Eukaryot Cell. 2013 Mar;12(3):411-9. doi: 10.1128/EC.00285-12. Epub 2013 Jan 11.

36.

Peptide antimicrobials: cell wall as a bacterial target.

Yount NY, Yeaman MR.

Ann N Y Acad Sci. 2013 Jan;1277:127-38. doi: 10.1111/nyas.12005. Epub 2013 Jan 9. Review.

PMID:
23302022
37.

Reduced vancomycin susceptibility in an in vitro catheter-related biofilm model correlates with poor therapeutic outcomes in experimental endocarditis due to methicillin-resistant Staphylococcus aureus.

Abdelhady W, Bayer AS, Seidl K, Nast CC, Kiedrowski MR, Horswill AR, Yeaman MR, Xiong YQ.

Antimicrob Agents Chemother. 2013 Mar;57(3):1447-54. doi: 10.1128/AAC.02073-12. Epub 2013 Jan 7.

38.

The RpoB H₄₈₁Y rifampicin resistance mutation and an active stringent response reduce virulence and increase resistance to innate immune responses in Staphylococcus aureus.

Gao W, Cameron DR, Davies JK, Kostoulias X, Stepnell J, Tuck KL, Yeaman MR, Peleg AY, Stinear TP, Howden BP.

J Infect Dis. 2013 Mar 15;207(6):929-39. doi: 10.1093/infdis/jis772. Epub 2012 Dec 18.

39.

NDV-3, a recombinant alum-adjuvanted vaccine for Candida and Staphylococcus aureus, is safe and immunogenic in healthy adults.

Schmidt CS, White CJ, Ibrahim AS, Filler SG, Fu Y, Yeaman MR, Edwards JE Jr, Hennessey JP Jr.

Vaccine. 2012 Dec 14;30(52):7594-600. doi: 10.1016/j.vaccine.2012.10.038. Epub 2012 Oct 22.

40.
41.

Integrative continuum: accelerating therapeutic advances in rare autoimmune diseases.

Van Herle K, Behne JM, Van Herle A, Blaschke TF, Smith TJ, Yeaman MR.

Annu Rev Pharmacol Toxicol. 2012;52:523-47. doi: 10.1146/annurev-pharmtox-010611-134628. Review.

PMID:
22235861
42.

Emerging themes and therapeutic prospects for anti-infective peptides.

Yount NY, Yeaman MR.

Annu Rev Pharmacol Toxicol. 2012;52:337-60. doi: 10.1146/annurev-pharmtox-010611-134535. Review.

PMID:
22235859
43.

Ampicillin enhances daptomycin- and cationic host defense peptide-mediated killing of ampicillin- and vancomycin-resistant Enterococcus faecium.

Sakoulas G, Bayer AS, Pogliano J, Tsuji BT, Yang SJ, Mishra NN, Nizet V, Yeaman MR, Moise PA.

Antimicrob Agents Chemother. 2012 Feb;56(2):838-44. doi: 10.1128/AAC.05551-11. Epub 2011 Nov 28.

44.

Efficacy of synthetic peptides RP-1 and AA-RP-1 against Leishmania species in vitro and in vivo.

Erfe MC, David CV, Huang C, Lu V, Maretti-Mira AC, Haskell J, Bruhn KW, Yeaman MR, Craft N.

Antimicrob Agents Chemother. 2012 Feb;56(2):658-65. doi: 10.1128/AAC.05349-11. Epub 2011 Nov 28.

45.

Context mediates antimicrobial efficacy of kinocidin congener peptide RP-1.

Yount NY, Cohen SE, Kupferwasser D, Waring AJ, Ruchala P, Sharma S, Wasserman K, Jung CL, Yeaman MR.

PLoS One. 2011;6(11):e26727. doi: 10.1371/journal.pone.0026727. Epub 2011 Nov 4.

46.

The Staphylococcus aureus two-component regulatory system, GraRS, senses and confers resistance to selected cationic antimicrobial peptides.

Yang SJ, Bayer AS, Mishra NN, Meehl M, Ledala N, Yeaman MR, Xiong YQ, Cheung AL.

Infect Immun. 2012 Jan;80(1):74-81. doi: 10.1128/IAI.05669-11. Epub 2011 Oct 10.

47.

Efficacy of NZ2114, a novel plectasin-derived cationic antimicrobial peptide antibiotic, in experimental endocarditis due to methicillin-resistant Staphylococcus aureus.

Xiong YQ, Hady WA, Deslandes A, Rey A, Fraisse L, Kristensen HH, Yeaman MR, Bayer AS.

Antimicrob Agents Chemother. 2011 Nov;55(11):5325-30. doi: 10.1128/AAC.00453-11. Epub 2011 Aug 22.

48.

In vitro cross-resistance to daptomycin and host defense cationic antimicrobial peptides in clinical methicillin-resistant Staphylococcus aureus isolates.

Mishra NN, McKinnell J, Yeaman MR, Rubio A, Nast CC, Chen L, Kreiswirth BN, Bayer AS.

Antimicrob Agents Chemother. 2011 Sep;55(9):4012-8. doi: 10.1128/AAC.00223-11. Epub 2011 Jun 27.

49.

Daptomycin resistance mechanisms in clinically derived Staphylococcus aureus strains assessed by a combined transcriptomics and proteomics approach.

Fischer A, Yang SJ, Bayer AS, Vaezzadeh AR, Herzig S, Stenz L, Girard M, Sakoulas G, Scherl A, Yeaman MR, Proctor RA, Schrenzel J, François P.

J Antimicrob Chemother. 2011 Aug;66(8):1696-711. doi: 10.1093/jac/dkr195. Epub 2011 May 28.

50.

Correlation of daptomycin resistance in a clinical Staphylococcus aureus strain with increased cell wall teichoic acid production and D-alanylation.

Bertsche U, Weidenmaier C, Kuehner D, Yang SJ, Baur S, Wanner S, Francois P, Schrenzel J, Yeaman MR, Bayer AS.

Antimicrob Agents Chemother. 2011 Aug;55(8):3922-8. doi: 10.1128/AAC.01226-10. Epub 2011 May 23.

Supplemental Content

Loading ...
Support Center